CMT-CNTNAP1

CNTNAP1 | 2019

What Is CMT-CNTNAP1?

CMT-CNTNAP1 is a type of CMT caused by autosomal recessive mutations in the CNTNAP1 gene. This gene provides instructions for making CASPR, a protein that anchors the paranodal junctions flanking the nodes of Ranvier in myelinated peripheral nerves, organizing the axon membrane into the distinct domains required for efficient nerve signal conduction. Mutations in the CNTNAP1 gene disrupt this organization, leading to impaired nerve signal transmission.

CMT-CNTNAP1 is autosomal recessive, meaning that both copies of the gene must have a mutation to cause this subtype.

Clinical Features

The age of symptom onset in CMT-CNTNAP1 is variable, ranging from childhood to adulthood. Symptoms typically begin in the lower extremities and progress over time to involve the upper limbs. Nerve conduction studies usually show somewhat slowed conduction velocities and reduced amplitudes, consistent with an axonal form of CMT.

CMT-CNTNAP1 symptoms may include:

  • Weakness in the feet and lower legs
  • Muscle atrophy
  • Foot drop
  • Reduced or absent reflexes
  • Reduced sensation
  • A steppage-style walking pattern
  • Foot deformities, including high arches, and hammertoes (clawed toes)
  • Progressive involvement of the hands and forearms
  • Difficulty with fine motor skills and manual dexterity
  • Additional symptoms not listed here

Disease Course

CMT-CNTNAP1 shows wide variability in severity and progression. Some individuals are mildly affected, while others develop a more severe disease. Disease progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
CMT-CNTNAP1

Classification
Unclassified Subtypes

Neuropathy Type
Axonal

Inheritance Pattern
autosomal recessive

Genetic Context

HGNC-Approved Gene Symbol
CNTNAP1

Gene Full Name
contactin associated protein 1

HGNC Gene Alias(es)
CASPR

Chromosome
17q21.2

Zygosity of Responsible Variant
Compound Heterozygous

Variant Mechanism

Loss of Function (LoF)

Details

Mechanistic basis:
Complete loss

Confidence:
High

Prediction:
The literature predicts a biallelic loss-of-function mechanism for CMT-CNTNAP1: nonsense, frameshift, and missense variants abolish or destabilize Caspr, the axonal neurexin-family protein that pairs with contactin-1 and glial neurofascin-155 to build the paranodal septate-like junction. Cntnap1-null mice lose the transverse bands of that junction and let juxtaparanodal potassium channels spread into the paranode, degrading saltatory conduction, the same failure seen in patients carrying two defective copies.

Rationale:
Caspr loss dismantles the axo-glial seal at the paranode, and the conduction findings follow from missing adhesion rather than from a mutant protein sitting in the junction. Missense alleles that cannot engage contactin-1 never reach the axon surface, which makes them functionally null and leaves nothing at the paranode to interfere with.

ClinVar Pathogenic Variants

View CNTNAP1 ClinVar Variants

CMT-CNTNAP1 OMIM Entry

CMT-CNTNAP1 OMIM

CNTNAP1 OMIM Entry

CNTNAP1 OMIM

More Info

CMT-CNTNAP1 Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

CNTNAP1 Mutations in an Adult with Charcot Marie Tooth Disease

Authors

Freed, A. S., Weiss, M. D., Malouf, E. A., & Hisama, F. M.

Publication Date
August 9, 2019

Updated: July 18, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


A Name That Does Too Much Work

Jean-Martin Charcot's name appears throughout medicine, but nowhere does it create more confusion than in the foot. Learn why the CMT foot and Charcot neuroarthropathy, also known as Charcot foot, share a name yet differ in how they develop, appear, and are managed.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.